Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Blood
|
February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
Titouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.
Haematologica
|
October 15, 2020
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
Jill Corre, Lydia Montes, Elodie Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome
Bruno Royer, Stéphane Minvielle, Momar Diouf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Blood
|
April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditions
Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Leukemia
|
July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B Hebraud, X Leleu, V Lauwers-Cances, et al.
Blood
|
October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Laurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
Blood
|
March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Blood
|
September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
Anaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Blood
|
February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
Titouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.
Haematologica
|
October 15, 2020
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
Jill Corre, Lydia Montes, Elodie Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome
Bruno Royer, Stéphane Minvielle, Momar Diouf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Blood
|
April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditions
Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Haematologica
|
April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Leukemia
|
July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B Hebraud, X Leleu, V Lauwers-Cances, et al.
Blood
|
October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Laurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
Blood
|
March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Blood
|
September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
Anaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
Page
of 6